FDA Approves Vaxneuvance Pneumococcal Vaccine for Infants, Children
The FDA has expanded the approval for Merck's Vaxneuvance for prevention of invasive disease caused by Streptococcus pneumoniae to include children 6 weeks through 17 years of age.
The FDA has expanded the approval for Merck's Vaxneuvance for prevention of invasive disease caused by Streptococcus pneumoniae to include children 6 weeks through 17 years of age.
Two Phase 3 studies of Merck's investigational 15-valent pneumococcal conjugate vaccine met their primary immunogenicity objectives.